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Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP), is selectively incorporated into melanoma cells and inhibits
their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock
protein (HSP) upon exposure to an alternating magnetic ﬁeld (AMF). This study tested if a chemo-thermo-immunotherapy (CTI
therapy) strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite
nanoparticles (NPrCAP/M). We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of
exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth. The therapeutic protocol
against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments
not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant.
The heat-generated therapeutic eﬀect was more signiﬁcant at a temperature of 43
◦C than either 41
◦Co r4 6
◦C. NPrCAP/M with
AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most signiﬁcant growth inhibition
of the re-challenge tumor and increased the life span of the mice. HSP70 production was greatest at 43
◦C compared to that with
41
◦Co r4 6
◦C. CD8+T cells were inﬁltrated at the site of the re-challenge melanoma transplant.
Copyright © 2009 Tomoaki Takada et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Melanogenesis is inherently cytotoxic and uniquely occurs in
melanocytic cells; thus, tyrosine analogs that are tyrosinase
substrates are good candidates for melanoma-speciﬁc target-
ing and therapy [1]. N-propionyl and N-acetyl derivatives
of 4-S-cysteaminylphenol (NPr- and NAcCAP) were syn-
thesized and found to possess both cytostatic and cytocidal
eﬀects on in vivo and in vitro melanomas through the
oxidative stress resulting from production of cytotoxic free
radicals [2–6]. We now provide evidence that the unique
melanogenesis cascade can be exploited for developing a
chemo-thermo-immunologic approach (CTI Therapy) tar-
geted to melanoma by conjugating NPrCAP with magnetite
nanoparticles (NPrCAP/M).
Magnetite nanoparticles have been employed for ther-
motherapy in a number of cancer treatments including
human prostate cancers [7–9]. They consist of 10–100nm2 Journal of Biomedicine and Biotechnology
sizedironoxide(Fe3O4)withasurroundingpolymercoating
and become magnetized when placed in an external alternat-
ing magnetic ﬁeld (AMF) [10]. In hyperthermia treatment,
the expression of heat shock proteins (HSPs) plays an
important role in immune reactions [11–19]. Accumulating
evidence from our group [20–23] and from others [24]
implicates HSP expression induced by hyperthermia in
tumorimmunityandopensthedoortocancertherapybased
on hyperthermia treatment (thermo-immunotherapy). In
such a strategy, a tumor-speciﬁc hyperthermia system that
can induce necrotic cell death via HSP expression without
damaging noncancerous tissues would be highly desirable.
An intracellular hyperthermia system using tumor-targeted
magnetite nanoparticles facilitates tumor-speciﬁc hyperther-
mia; this can induce necrotic cell death via HSP expression,
which in turn induces antitumor immunity.
We synthesized, in our initial study, magnetite cationic
liposomes (MCLs) loaded with 4-S-cysteaminylphenol
(CAP) [25]. There was, however, a risk of nonspeciﬁc
electrostatic interaction between MCLs and various non-
target cells. A promising technique is the use of tumor-
targeted magnetite nanoparticles, and this approach is
extendedbysynthesizinganothertypeofmagnetitenanopar-
ticles, NPrCAP/M, on which NPrCAP is superﬁcially and
directly bound on the surface of magnetite nanoparticles.
NPrCAP/M is chemically stable and can be produced in
large quantities and employed to eﬀect melanoma-targeted
chemotherapy (by NPrCAP) and thermoimmunotherapy
(by magnetite with HSP). In this study, we evaluated their
thermo-therapeutic eﬀect on distant metastatic melanomas,
using the mouse B16 melanoma system. Speciﬁcally we
assessed the in vivo growth inhibition of a subsequently
transplanted melanoma growth (re-challenge melanoma)
after treating the initial melanoma transplant. We also
investigated the possible association of HSP production with
growth inhibition of the re-challenge melanoma.
2.MaterialsandMethods
2.1. Preparation of NPrCAP/M. The details of the prepa-
ration of NPrCAP/M are described elsewhere [26]. Brieﬂy,
magnetitenanoparticles(Fe3O4;averageparticlesize,10nm)
were coated with aminosilane and conjugated with NPrCAP
via maleimide cross-linkers. The resultant NPrCAP/M was
s u s p e n d e di n1 0m Lo fH 2O. The degree of incorporation of
NPrCAP to magnetite was 61.0nmol/mg magnetite.
2.2. Cells and Animal Models. All of the animal experiments
were conducted by an approval of Animal Experiment Ethics
Committee of Sapporo Medical University. All the surgical,
transplantation and drug administration procedures were
carried out after anesthesia by diethyl ether. Mouse B16F1
and B16F10 and B16 OVA melanoma cells (3.0 × 105)i n
0.1mL of phosphate-buﬀered saline (PBS) were s.c. trans-
planted into the right ﬂanks of 4-week-old female C57BL/6
mice (weighing approximately 10.0g and purchased from
Hokudo Laboratory, Sapporo, Japan). B16F1 and B16F10
cells were purchased from ATCC (Summit Pharmaceuticals
Intl.Corp.,Tokyo,Japan).B16OVAisaB16F1melanomacell
line stably transfected with chicken ovalbumin (OVA) cDNA
and was kindly provided by Dr. Y. Nishimura, Kumamoto
University, Kumamoto, Japan [27]. On day 5 after trans-
plant mice with primary melanoma transplantation were
randomly divided into treatment groups. With a 26-gauge
microsyringe, the B16 melanoma-bearing mice were injected
with 0.1mL of NPrCAP/M (40.0mg/mL solution) directly
into the tumor site in a single-dose administration (approx-
imately 0.5μL/mm3 tumor volume). Treated tumors on the
right ﬂank in mice were excised on day 13 after the ﬁrst
s.c. transplantation. On day 40 after the surgical excision
(on day 53 after primary transplantation), mice were re-
challenged with 1.0 × 105 B16 cells which were injected
into the left ﬂank. The total number of melanoma cells
at the re-challenge experiments was 1/3 of melanoma cells
as that of the primary transplants because there was no
NPrCAP/M administration which might cause some tissue
destruction. The control group, naive mice of the same age
and sex, received transplantation of melanoma cells into the
right ﬂank as with the treated groups. On day 14 after the
secondary transplantation (day 67 after primary transplan-
tation), tumor diameters were measured in millimeters with
calipers, and tumor volumes were calculated by the formula:
long axis×(short axis)
2×0.5.Themic einthetr eat edgr oups
were judged to be tumor free (rejection) if the tumor was less
than about 2mm in diameter by palpation on day 60 after
the secondary transplantation (day 113 after the primary
transplantation).
2.3. Magnetite-Nanoparticle-Mediated Hyperthermia. An
alternating magnetic ﬁeld (AMF) was generated using a
horizontal coil (inner diameter: 7cm; length: 7cm) with a
transistor inverter (LTG-100-05; Dai-ich High-Frequency
Co., Tokyo, Japan). The magnetic ﬁeld frequency and
intensity were 118kHz and 30.6kA/m (384Oe), respectively.
Mice were exposed to the AMF inside the coil for 15
or 30 minutes. Surface (peripheral) and core (central)
temperatures of the tumor were continuously monitored
and measured using two optical ﬁber probes (FX-9020;
Anritsu Meter, Tokyo, Japan); that is, one inserted into
the tumor core and another ﬁxed on the tumor surface.
M e a s u r e m e n tt i m ep o i n t sw e r e0 ,1 ,2 ,3 ,4 ,5 ,1 0 ,1 5 ,
20, 25, 30, 31, 32, 33, 34, and 35 minutes for 30 minutes
thermotherapy. The therapeutic temperatures at 41
◦C,
43
◦Co r4 6
◦C were monitored by measuring the surface
temperature and adjusting the transistor inverter during
exposure to AMF (Figures 1(a), 1(b),a n d1(c)).
2.4. Treatment Protocols. Animal experiments were carried
out using the four protocols described below. Each exper-
imental group of Protocols number 1 through number 4
consisted of six to eleven mice. All the treatment protocols
were again approved by the Animal Experimental Ethics
CommitteeofSapporoMedicalUniversity.Theexperimental
conditions for melanoma transplantation and the methods
of NPrCAP/M administration were identical in all four
protocols and all the animal experiments including drugJournal of Biomedicine and Biotechnology 3
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Figure 1: Shifts of temperatures at the core and the surface of tumors during AMF exposure. The temperature at the tumor surface was
maintained at 41
◦C( a ) ,4 3
◦C( b ) ,a n d4 6
◦C (c) for 30 minutes by adjusting the power of the AMF generator. Temperatures of both the
tumor surface and core were measured simultaneously.
administration were carried out after anesthesia by diethyl
ether.
2.4.1. Protocol Number 1: Eﬀect of NPrCAP/M with and
without AMF on Re-Challenge Tumor Growth. On day 5 after
the s.c. transplantation of B16 melanoma cells, mice were
divided into four groups. In Groups I and II mice received
s.c. administration of 0.1 mL of 40.0mg/mL aminosilane-
coated magnetite (M) once a day every other day for a
total of three days (days 6, 8, and 10) with AMF (Group
II) or without AMF (Group I). In Groups III and IV mice
received s.c.administration of 0.1 mL of NPrCAP/M (4.0 mg
magnetite equivalent) once a day every other day for a total
of three days (days 6, 8, and 10) with (Group IV) or without
(Group III) AMF. The temperature at the tumor surface
was maintained at 43
◦C during exposure for 30 minutes by
controlling AMF intensity. Mice of a control group of the
same age and sex received s.c. transplantation of melanoma
cells into the right ﬂank, as with the treated groups. On
day 13 after the primary transplantation all mice underwent
total resection of melanoma nodules. On day 53 after the
ﬁrst transplantation (postoperative day 40), surviving mice
in each group received a second transplantation of B164 Journal of Biomedicine and Biotechnology
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Figure 2: Growth curves of primary B16 melanomas. Experimental conditions and statistical analyses of (a), (b), (c) and (d) are identical
to those of Protocol number 1. (a) Growth curve of B16F1 melanoma cells treated with NPrCAP/M alone without heat (n = 10) and
with heat by AMF exposure (n = 10) at days 6, 8, and 10. These two groups showed a signiﬁcant growth inhibition compared to that of
control naive mice (n = 10) by Dunnet’s test (P<. 01). Importantly, there is no signiﬁcant diﬀerence between the two groups with and
without AMF exposure. (b) Growth curve of B16F1 melanoma cells treated with magnetite alone (n = 10) and NPrCAP/M alone without
AMF exposure (n = 10). Mice with magnetite alone did not show any growth inhibition whereas NPrCAP/M alone resulted in a signiﬁcant
growthinhibitionofprimarymelanoma(P<. 01).(c)ComparisonofgrowthinhibitionofB16F10primarymelanomasaftertreatmentwith
NPrCAP/M with AMF exposure. Compared to control naive mice (n = 10) transplanted with B16F10 cells without any treatment, those
mice (n = 10) with NPrCAP/M plus AMF exposure showed a signiﬁcant growth inhibition of primary B16F10 melanomas with a similar
degree to that of B16F1 melanoma (Figure 2(a)) (P<. 01 by Dunnet’s test). (d) Comparison of the growth inhibition of B16F10 secondary,
re-challenge melanoma. The mice (n = 10) with NPrCAP/M plus AMF exposure showed a marked growth inhibition compared to control
naive mice without any treatment (n = 10).Journal of Biomedicine and Biotechnology 5
melanoma cells into the opposite ﬂank. Tumor volumes were
calculated at day 14 after the second transplantation of B16
melanoma cells.
2.4.2. Protocol Number 2: Eﬀect of Treatment Frequency
with NPrCAP/M on Re-Challenge Tumor Growth. Mice were
randomly divided into six treatment groups. They were
exposed to AMF once on day 6 (Group I), twice (on days
6 and 8) (Group II), twice (on days 6 and 10) (Group III),
three times (on days 6, 8, and 10) (Group IV), three times
(on days 6, 7, and 8) (Group V), and ﬁve times (on days 6
through 10) (Group VI).
2.4.3. Protocol Number 3: Eﬀect of Temperature and Treatment
Frequency of NPrCAP/M with AMF on Re-Challenge Tumor
Growth. Mice were divided into six groups. Mice of Groups
I and II were exposed to the AMF to maintain the surface
temperature at 41
◦C once a day for two days (days 6 and 10)
and for three days (days 6, 8, and 10), respectively. Using the
same day schedule mice of Groups III and IV were exposed
to the AMF at 43
◦C and mice of Groups V and VI at 46
◦C.
2.4.4. Protocol Number 4: Eﬀect of Temperature and Treatment
Duration on Re-Challenge Tumor Growth. Mice were divided
into four groups. Temperatures at the surface of the tumors
in Groups I and II were maintained at 43
◦Ca n d4 6
◦C,
respectively, during AMF exposure for 15 minutes. The
surface temperatures in Groups III and IV were maintained
at 43
◦Ca n d4 6
◦C, respectively, during therapy for 30
minutes.
2.5. ELISA for Heat Shock Protein 70 (HSP70) Expression in
aT u m o r . After thermotherapy, the amount of HSP70 in the
primarytumorwasmeasuredusinganHSP70EIAKit(Stress
Gen Biotechnologies, British Columbia, Canada) according
to the manufacturer’s instructions. The total protein content
of the tumor homogenates was determined using the BCA
Protein Assay Kit (Pierce Biothechnology, Inc., USA). The
control group was composed of mice without NPrCAP/M
administration or AMF exposure. Group I received s.c.
administration of NPrCAP/M directly at the tumor site
once a day without AMF exposure. Mice of Groups II and
III received thermotherapy at 41
◦C for 15 minutes and 30
m i n u t e s ,G r o u p sI Va n dVa t4 3
◦C for 15 minutes and 30
m i n u t e s ,a n dG r o u p sV Ia n dV I Ia t4 6
◦Cf o r1 5m i n u t e s
and 30 minutes, respectively. Then, 24 hours later, all tumors
wereremoved,andtheirlysateswereprocessedfortheHSP70
assay. In separate groups, tumors were excised at 24, 48, and
72 hours after the 43
◦C thermotherapy for 30 minutes, and
amounts of HSP70 were measured.
2.6. Histological and Immunohistochemical Study. After ther-
motherapy in the primarily transplanted melanoma at 43
◦C
for 30 minutes once a day for three days (Figure 4(a),
Group IV), melanomas in re-challenge mice were excised
on the 18th day after second transplantation of B16F1 cells.
Paraﬃn-embedded sections were prepared and processed for
HE staining. The frozen tumor tissues were stained with
antimouse CD4 (Santa Cruz Biotechnology Inc., CA, USA)
or CD8 (Chemicon International Inc., CA, USA).
2.7. Statistical Analysis. Data were analyzed by one- or two-
way analysis of variance (ANOVA), and then diﬀerences
in experimental results for tumor growth and expression
of HSP were assessed by Sheﬀe’s test to compare all the
experimental groups, or by Dunnett’s test, which compared
the experimental versus the control groups. Diﬀerences in
survival rates were analyzed by the Kaplan-Meier method
and log-rank test with Bonferroni correction for multiple
comparisons. The level of signiﬁcance was P<. 05 (two-
tailed). All statistical analyses were performed using Stat
View J-5.0 (SAS Institute Inc. Cary, NC).
3. Results and Discussion
In the search for successful cancer treatment it is self-evident
that the exploitation of a speciﬁc biological property is one
of the best approaches for developing the targeted therapy
[27, 28]. We have previously shown that the melanogenesis
substrate, NPrCAP, is a good candidate for developing
melanoma chemotherapy because melanogenesis is uniquely
expressed in melanocytic cells and is inherently cytotoxic
from the action of tyrosinase on tyrosine with forma-
tion of highly reactive free radicals [1, 4]. Nanoparticles
may also provide a good platform to coadminister anti-
cancer therapeutics directed at diﬀerent targets. Speciﬁcally
hyperthermia with the use of magnetite nanoparticles has
been shown to possess great potential to develop thermo-
immunotherapy [23, 29]. In this study the conjugate of
NPrCAP and magnetite nanoparticles, NPrCAP/M was
synthesized with the hope of developing a chemotherapeutic
as well as a thermo-immunotherapeutic eﬀect. We employed
two cell lines of B16 melanoma, that is, B16F1 and B16F10,
and B16OVA cells and compared the thermo-therapeutic
protocols in detail by evaluating the growth of the re-
challenge melanoma as well as the duration and rates of
survival of melanoma-bearing mice.
3.1. Immediate and Steady Generation of Heat by Intratumor
Administration of NPrCAP/M with AMF Exposure on B16
Melanoma Nodules. In the previous intratumor MCL hyper-
thermia for B16 melanoma the skin surface temperature
above the subcutaneous tumor rose to 43 or 46
◦C[ 29].
To obtain a rapid and steady temperature increase at the
core and the surface of the B16 melanoma, NPrCAP/M
was injected into the center of the tumor nodules, and
internal and surface tumor temperatures were measured
during AMF exposure. Both temperatures increased within
one minute to the target of 41
◦C, 43
◦C, or 46
◦C (Figures
1(a), 1(b),a n d1(c)), indicating that NPrCAP/M injection
followed by AMF exposure could immediately and steadily
heat the subcutaneously transplanted melanoma nodules.
The temperature at the tumor center was approximately 2◦C
higher than that at the tumor surface.6 Journal of Biomedicine and Biotechnology
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Figure 3: Time schedules and results for tumor volumes, survival periods, and rates of mice treated by the Protocol number 1. (a) Protocols
of Groups I, II, III, and IV. (b) Tumor volumes of re-challenge B16F1 melanoma on day 14. All data are presented as mean ± standard
deviation. Tumor volumes of Group IV were signiﬁcantly reduced compared with those of the control group (P = .0295) or Group I
(P = .0215). There were no signiﬁcant interactions between drugs and AMF (P = .5568). (c) Kaplan-Meier survival curve over a period of
60 days after tumor re-challenge in Protocol number 1.
3.2. Eﬀective and Equal Inhibition of B16 Melanoma Growth
at the Site of Primary Transplantation by Intratumor Admin-
istration of NPrCAP/M with and without Heat. We ﬁrst
evaluated the chemotherapeutic eﬀe c to fN P r C A P / Mw i t h
or without heat. NPrCAP/M without heat inhibited the
growth of primary transplants to the same degree as did
NPrCAP/M with heat, indicating that NPrCAP/M alone
has a chemotherapeutic eﬀect. The critical temperature for
thermotherapy was documented to be 43
◦Cf o rv a r i o u s
cell lines [7, 8]. Using two melanoma cell lines, B16F1,
and B16F10 and B16OVA, we examined melanoma growth
inhibitionbyintra-tumoradministrationofNPrCAP/Minto
primary tumors on days 6, 8, and 10 after transplantation
with exposure to AMF at 43
◦C for 30 minutes (Figures 2(a)
and 2(c)) under the experimental conditions of Protocol
number 1 (Figure 3(a)). Both NPrCAP/M with and without
AMF exposure resulted in a signiﬁcant and equal reduction
of melanoma tumor volume in both B16F1 and F10 cellsJournal of Biomedicine and Biotechnology 7
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Figure 4: Time schedule and results for tumor volumes, survival periods, and rates of mice treated by Protocol number 2. (a) Protocols of
Groups I, II, III, IV, V, and VI. (b) Tumor volumes on day 14 after re-challenge with B16F1 melanoma. All data are presented as mean ±
standard deviation. Tumor volumes of Groups III and IV were found to be signiﬁcantly reduced compared with those of the control group
(P = .0411 and .0195, resp.) and Group VI (P = .0444 and .0237, resp.) by the Scheﬀ´ e test. (c) Kaplan-Meier survival curves over a period of
60 days after re-challenge with B16F1. The survival rate of Group III was signiﬁcantly prolonged compared with those of the control group
(P = .0006) and Group VI (P = .0013). The survival rate of Group IV was signiﬁcantly prolonged compared with that of the control group
(P< . 0001), Group I (P = .0014), Group II (P = .0014), and Group VI (P = .0013). One of the eight mice in Group III and three of the
nine mice in Group IV were protected against re-challenge with B16F1 melanoma cells.
at the site of primary transplantation (P<. 01 by two-
way repeated measure ANOVA, Figures 2(a) and 2(c))
compared to tumor volume of naive control mice. B16
OVA cells also gave the same experimental results (data
not shown). Control studies comparing magnetite alone
and magnetite plus NPrCAP (NPrCAP/M) without AMF
exposure showed that magnetite alone does not have any
melanoma growth inhibiting eﬀect whereas NPrCAP/M
without AMF signiﬁcantly inhibited melanoma-growth (P<
.01 by two-way repeated measure ANOVA, Figure 2(b)).
Since we obtained basically same growth inhibition results
for both the primary and secondary transplants from the8 Journal of Biomedicine and Biotechnology
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Figure 5: Time schedules and results for tumor volume, survival periods and rates of mice treated by Protocol number 3. (a) Protocols of
Groups I, II, III, IV, V, and VI. (b) Tumor volumes on day 14 after re-challenge with B16F1 melanoma. All data are presented as mean ±
standard deviation. Tumor volumes of Groups III, IV, and V were signiﬁcantly reduced compared with the control group (P = .0045,.0004,
and .0085 resp.) by the Scheﬀ´ e test. (c) Kaplan-Meier survival curve over a period of 60 days after tumor re-challenge. Survival rates of
Groups III and IV were signiﬁcantly prolonged compared with that of the control group (P = .0011 and .0002, resp.). One of the nine mice
in Group III and four of the nine mice in Group IV were protected against re-challenge with B16F1 melanoma cells.
two cell lines, the majority of subsequent studies listed in
Protocols number 1 through number 4 were conducted on
B16F1 cells.
3.3. Eﬀective Growth Inhibition of B16F1 Melanoma Cells
at the Site of Re-Challenge, Second Transplantation by
NPrCAP/M with AMF Exposure (Protocol number 1). We
then evaluated whether NPrCAP/M treatment with or
without heat in the local primary tumor could inhibit the
growth of distant tumors which were not given an intra-
tumor injection of NPrCAP/M. There was a signiﬁcant
diﬀerenceinthemelanomagrowthinhibitionofre-challenge
transplants between the groups of NPrCAP/M with and
without heat. NPrCAP/M with AMF exposure showed the
mostsigniﬁcantgrowthinhibitioninre-challengemelanoma
and increased life span of the host animals, that is, 30%–
50% complete growth inhibition (rejection) of re-challenge
melanoma growth, indicating that NPrCAP/M with heat
possesses a thermo-immunotherapeutic eﬀect. For this, we
treated the primary B16F1 and F10 melanoma cells by
NPrCAP/M and then measured the volume of the secondary
melanoma after the second transplantation at a diﬀerent site
to the ﬁrst transplant. We also evaluated the survival periodsJournal of Biomedicine and Biotechnology 9
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Figure 6: Time schedules and results for tumor volumes, survival periods, and rates for treatment with Protocol number 4. (a) Protocols
of Groups I, II, III, and IV. (b) Tumor volumes on day 14 after re-challenge with B16F1 cells. All data are presented as mean ± standard
deviation. Tumor volumes of Groups I and III on day 14 were signiﬁcantly reduced compared with that of the control group (P = .0009 and
.0016, resp.) by Scheﬀ´ e test. (c) Kaplan-Meier survival curve over a period of 60 days after re-challenge. Survival rates of Group I and III were
signiﬁcantly prolonged compared with that of the control group (P = .0004 and .0005, resp.). Four of the eight mice in Group I and three of
the seven mice in Group III were protected against re-challenge with B16F1 melanoma cells. (d) Tumor volumes of the primary tumor and
re-challenge tumor as representative examples of Groups I (n = 8) and IV (n = 10) which were treated at 43
◦C for 15 minutes and 46
◦Cf o r
30 minutes, respectively. All data are presented as mean ± standard deviation.
and rates of host melanoma-bearing mice. These secondary
melanomas were not directly exposed to NPrCAP/M; hence
we could evaluate the thermo-immunotherapeutic eﬀect of
NPrCAP/M treatment.
First,wecomparedthetherapeuticeﬀectsamongGroups
I (intratumor injection of magnetite nanoparticles alone
without AMF exposure), II (magnetite injection and heat
at 43
◦C for 30 minutes by AMF), III (NPrCAP/M injec-
tion without AMF), and IV (NPrCAP/M injection and
heat at 43
◦Cf o r3 0m i n u t e sb yA M F )o fP r o t o c o ln u m -
ber 1 (Figure 3(a)). As shown in Figure 3(b),N P r C A P / M -
mediated hyperthermia at 43
◦C showed the most signiﬁcant10 Journal of Biomedicine and Biotechnology
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Figure 7: Expression of HSP70 in a tumor after thermotherapy. (a) Amounts of HSP70 in tumors 24 hours after thermotherapy as described
in the Materials and Methods. All data are presented as mean ± standard deviation (n = 4). There were signiﬁcant diﬀerences between
the control group and all other groups except Group I by Dunnett’s test (P<. 05). (b) Amounts of HSP70 24, 48, and 72 hours after
thermotherapy at 43
◦C for 30 minutes. All data are presented as mean ± standard deviation (n = 4). There were signiﬁcant diﬀerences
between the control group and all other groups by Dunnett’s test (P<. 05).
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Figure 8: Histopathology and immunohistochemistry of a re-challenge tumor. (a) A low-power view of a re-challenge tumor with HE
staining (×49). (b) A high-power view (×200). Monocytic inﬁltrates are seen around a necrotic lesion. (c) CD4+ Tc e l l s( ×400). (d) CD8+T
cells (×400). Almost equal numbers of CD4+ and CD8+ T cells are observed.
growth inhibition of secondary B16F1 melanoma in re-
challenged mice. Both magnetite nanoparticles with heat at
43
◦C and NPrCAP/M without heat also inhibited the growth
of secondary melanomas, though statistically not signiﬁ-
cant (Figure 3(b) and (c)). Most importantly, NPrCAP/M
alone without heat caused equal growth inhibition of sec-
ondary melanomas to that induced by magnetite with AMF
exposure, suggesting some immunotherapeutic eﬀect of
NPrCAP/M. A similar growth inhibition of secondary trans-
planted melanoma cells was obtained in B16F10 (Figure 2).Journal of Biomedicine and Biotechnology 11
Next, we compared the life span of the host animals
among 4 groups. The survival of mice in Group IV was
prolonged, compared with that of the control group (P =
.0003) and Group I (P = .0003). Three of the ten mice
in Group IV (30%) were protected completely from re-
challenge with B16F1 cells (Figure 3(c)). Magnetite alone
with AMF exposure at 43
◦C( G r o u pI I )a n dN P r C A P / M
alonewithoutheat(GroupIII)failedtoshow anystatistically
signiﬁcant prolongation of the host animal survival.
3.4. Eﬀect of Treatment Frequency for the Primary Tumor
on Growth Inhibition of Re-Challenge Melanoma (Protocol
number 2). To evaluate the eﬀect of the number of treat-
ments for the primary tumor on the re-challenge tumor, six
treatment approaches were designed using B16F1 cells. They
consisted of hyperthermia once on day 6 (Group I), twice
on days 6 and 8 (Group II) or days 6 and 10 (Group III),
t h r e et i m e so nd a y s6 ,8 ,a n d1 0( G r o u pI V )o r6 ,7 ,a n d8
(Group V), and a total of ﬁve times on days 6 through 10
(Group VI) (Figure 4(a)). Melanoma tumor volumes in re-
challengedmice were smallest in Groups III and IV, while the
longest survival periods and rates were obtained in Group
IV with complete growth inhibition (rejection) of second
re-challenge being 33% (n = 9) on day 60 (Figures 4(b)
and 4(c)). The consecutive irradiation on days 6, 7, and 8
(Group V) or days 6 through 10 resulted in larger volumes
of secondary tumors and poorer survival periods and rates
compared to Group III or IV (Figures 4(b) and 4(c)). These
ﬁndings suggested that repeated hyperthermia, once a day
everyotherdayforatotalofthreedays,couldinduceeﬀective
degradation of B16 melanoma cells, which then most likely
induced host immunity against melanoma.
3.5. Eﬀect of Temperature and Treatment Frequency on
Melanoma Growth Inhibition in Re-Challenge Mice (Protocol
number 3). Our study indicated that the most eﬀective
thermo-immunotherapyforre-challengeB16melanomacan
be obtained at a temperature of 43
◦C for 30 minutes with the
treatment repeated three times on every other day intervals
without complete degradation of the primary melanoma.
We compared growth inhibition of secondly transplanted
melanomas at therapeutic temperatures of 41
◦C, 43
◦C, and
46
◦C for 30 minutes twice on days 6 and 10, or three times
on days 6, 8, and 10 (Figure 5(a)). As shown in Figures 5(b)
and 5(c), thermotherapy at 43
◦Ci nG r o u pI V( 4 3
◦C, every
other day for a total of three times on three days) was the
most eﬀective for the growth inhibition of both the secondly
transplanted, re-challenge melanoma and for improving the
survival rates and duration of host mice. Four of the nine
mice in Group IV (44.4%) were protected completely against
re-challenge with B16F1 melanoma on day 60 (Figure 5(c)).
Our therapeutic conditions and their eﬀects diﬀer
from those of magnetically mediated hyperthermia on the
transplanted melanomas reported previously [29]. MCL-
mediated hyperthermia for B16 melanoma showed that
hyperthermia at 46
◦C once or twice led to regression of
40%–90% of primary tumors and to 30%–60% survival
of mice, whereas hyperthermia at 43
◦C failed to induce
regression of the secondary tumors with 0% survival of mice
[29].
3.6. Eﬀect of Temperature and Treatment Duration on
Melanoma Growth Inhibition in Re-Challenge Mice (Protocol
number 4). We then compared the eﬀects of temperature
and duration of NPrCAP/M-mediated hyperthermia at 43
◦C
for 15 minutes, 43
◦C for 30 minutes, 46
◦Cf o r1 5m i n u t e s ,
and 46
◦C for 30 minutes on the re-challenge with B16F1
melanoma (Figure 6(a)). Tumor volumes and survival rates
and periods of treatment of mice clearly showed that
hyperthermia at 43
◦C elicited a more signiﬁcant eﬀect than
t h a ta t4 6
◦C (Figures 6(b) and 6(c)). Four of the eight mice
(50%) in Group I (43
◦C for 15 minutes) and three of the
seven mice (42.8%) in Group III (43
◦Cf o r3 0m i n u t e s )
survived 60 days after a second transplantation of B16F1
(Figure 6(c)), suggesting that NPrCAP/M with heat to the
primary melanoma at 43
◦C for 15–30 minutes inhibits
signiﬁcantly the growth of distant metastatic melanoma,
complete growth inhibition (rejection) of the second re-
challengemelanomabeing42%–50%.Hyperthermiaat46
◦C
for 30 minutes strongly inhibited the growth of the B16F1
tumorbuthadlittleeﬀectonthere-challengetumor,whereas
hyperthermia at 43
◦C for 15 minutes hardly inhibited the
growth of the primary tumor but strongly inhibited that of
the second re-challenge tumor (Figure 6(d)). These ﬁndings
suggest that NPrCAP/M-mediated hyperthermia at 43
◦C
can be used most eﬀectively to treat distant metastatic
melanoma.
3.7. Production of HSP70 by NPrCAP/M Treatment and
Presence of CD8+ T Cells around and within the Re-
Challenge Melanoma. Heat shock protein forms a complex
with intracellular peptides released from degrading tumor
cells and presented by the MHC class I molecules of pro-
fessional antigen-presenting cells [23]. We analyzed HSP70
production in the primary tumor and CD4+ and CD8+
T cell inﬁltration into the re-challenge secondary tumor.
Figure 7(a) shows the amounts of HSP70 in the tumors
at 24 hours after the NPrCAP/M-mediated hyperthermia.
Amongthesixtreatmentgroups,conditionsofhyperthermia
at 43
◦C for 15 or 30 minutes and 46
◦Cf o r1 5m i n u t e sw e r e
equally eﬀective for induction of HSP70 as those at 41
◦C
for 15 minutes or 30 minutes and at 46
◦Cf o r3 0m i n u t e s
(Figure 7(a)). We also investigated whether expression of
HSP70 in the posttherapeutic tumors depended on the
duration of AMF exposure (15 minutes or 30 minutes),
heatingtemperature(41
◦C,43
◦C,or46
◦C),andtimeelapsed
after exposure (24 hours, 48 hours, or 72 hours). Figure 7(b)
shows that the amount of HSP70 in the treated B16F1
tumors was most abundant at 24 hours after hyperthermia
at 43
◦C, and over-expression of HSP70 was maintained at
a signiﬁcant level after 72 hours. Although thermotherapy
at 46
◦C for 15 minutes could induce HSP70 as abundantly
as that at 43
◦Cf o r3 0m i n u t e s( Figure 7(a)), this condition
failed to suppress the re-challenge melanoma transplant as12 Journal of Biomedicine and Biotechnology
eﬃciently as 43
◦C thermotherapy (Figures 5(b) and 5(c)).
This suggests that immunological factors other than HSPs
are at least in part responsible for growth inhibition and
rejection of the re-challenge melanoma. Hyperthermia at
43
◦C for 1 hour mediated the expression of MHC class
I molecules after 24 hours in association with enhanced
expression of HSP70 [30]. Heat treatment of tumor cells
permits enhanced cross-priming, possibly via up-regulation
of both HSPs and tumor antigen expression [24]. By
inducing HSP70 and possibly MHC class I, immune T cells
could aggregate around melanoma cells. We thus examined
histochemicallytheimmunologicalreactionagainstsecondly
transplanted, re-challenge B16F1 melanoma in hematoxylin
and eosin (HE)- and CD4- and CD8-stained sections.
In addition to neutrophilic leukocytes, macrophages, and
plasma cells, CD4+ and CD8+ T cells were observed around
and within the re-challenge tumors with necrotic lesions
(Figures 8(a), 8(b), 8(c),a n d8(d)). These T cells were seen
with a small number around the ﬁrst transplant melanoma
treated by NPrCAP/M with or without AMF exposure but
hardly observed around the naive B16F1 tumors in mice that
were not treated by NPrCAP/M-mediated thermotherapy
(data not shown). This may indicate that melanoma-speciﬁc
T cell immunity is likely involved in our NPrCAP/M therapy
strategy.
4. Conclusions
This study has provided the basis for developing a melanoma
targeted chemo-immuno-thermotherapy (CTI) strategy by
conjugating melanogenesis substrate, NPrCAP with mag-
netite nanoparticles after exposure to alternating magnetic
ﬁeld. NPrCAP/M-mediated hyperthermia at a relatively
low temperature (43
◦C) eﬀectively inhibited the growth of
second transplant, re-challenge melanoma. Possibly, superﬁ-
cially bound NPrCAP possesses important roles in targeting
nanoparticles to melanocytic cells and a chemotherapeutic
eﬀect on these cells. Based upon the present animal thera-
peutic protocol, that is, three-every-other-day treatment at
43
◦C, we have started preliminary clinical trials (phase I/II)
of NPrCAP/M CTI therapy with a signiﬁcant success to a
limited number of advanced stages III and IV melanoma
patients. Four patients entered in this trial after approval of
theEthicsCommitteeofSapporoMedicalUniversityandtwo
of them showed PR and CR, still surviving and carrying out
normal daily life for more than 24 months [31].
Lastly,itshouldbenotedthatmelaninintermediatespro-
duce reactive oxygen species such as superoxide and H2O2
[4, 32, 33]. This unique biological property of melanin inter-
mediates not only causes cell death but also may produce
immunogenic properties. In fact, NPrCAP/M alone without
heat was as eﬀective as magnetite nanoparticles with AMF
exposure in inhibiting growth of re-challenge melanoma
(Figures 3(b) and 3(c)). It would be interesting to know
whether the growth of secondary re-challenge melanoma
could be inhibited after treatment of NPrCAP alone onto
the primary tumor [34]. The molecular background of our
NPrCAP/M CTI therapy needs to be further studied.
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